{Reference Type}: Journal Article
{Title}: Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology.
{Author}: Alonso F;Martín de Francisco ÁLM;Auñón P;García-Carro C;García P;Gutiérrez E;Mcía M;Quintana LF;Quiroga B;Soler MJ;Torregrosa I; ;
{Journal}: Nefrologia (Engl Ed)
{Volume}: 43
{Issue}: 5
{Year}: 2023 Sep-Oct 23
暂无{DOI}: 10.1016/j.nefroe.2023.11.001
{Abstract}: The most widely used approach in the immunotherapy treatment of cancer is the administration of monoclonal antibodies directed against regulatory molecules of immune control that inhibit the activation of T cells, the so-called check point inhibitors (ICI). ICI nephrotoxicity epidemiology and pathology; its diagnosis with or without kidney biopsy; the type and duration of treatment; the possibility of rechallenging after kidney damage; and its indication in patients with cancer and renal transplantation are certainly controversial. In the absence of definitive studies, this document is intended to specify some recommendations agreed by the group of Onconephrology experts of the Spanish Society of Nephrology in those areas related to ICI nephrotoxicity, in order to help decision-making in daily clinical practice in Onconephrology consultations.